-
Product Insights
Net Present Value Model: TLX-101
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model TLX-101 Drug Details ACD-101 (131I-ACD-101) is...
-
Product Insights
Net Present Value Model: TLX-591
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model TLX-591 Drug Details TLX-591 is under...
-
Product Insights
Net Present Value Model: TLX-66
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model TLX-66 Drug Details TLX-66 is under...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – TLX-66
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry TLX-66 Drug Details TLX-66 is under development for the treatment of acute myeloid leukemia,...
-
Product Insights
Prostate Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Prostate cancer usually occurs in older men. Its symptoms include problems while urinating, decreased force in the stream of urine, blood in the urine, pain in the lower back, hips, or thighs, bone pain, and erectile dysfunction. The Prostate Cancer pipeline market research report provides comprehensive information on the therapeutics under development for Prostate Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – TLX-250
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry TLX-250 Drug Details TLX-250 is under development for the treatment of patients with advanced...
-
Product Insights
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Chronic myeloid leukemia (CML), also known as chronic myelogenous leukemia, is a type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood. Risk factors for CML include high-dose radiation, age, and gender. Symptoms include weakness, fatigue, night sweats, weight loss, fever, bone pain, an enlarged spleen, and pain or a sense of fullness in the belly. Treatment includes radiation therapy, blood cell transplantation, and chemotherapy. The CML pipeline drugs market research report provides...
-
Product Insights
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Acute lymphocytic leukemia (ALL) is a cancer of the white blood cells due to the production of a large number of immature lymphocytes thus blocking the production of normal blood cells. Risk factors for ALL include exposure to radiation or chemicals, age, virus infections, and genetic factors. Symptoms include anemia, frequent infections, easy bruising, bone pain, and breathing problems. Treatment includes chemotherapy, transfusions, transplant, and medications. The ALL pipeline drugs market research report provides comprehensive information on the therapeutics under...
-
Product Insights
Pancreatic Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pancreatic Cancer – Drugs In Development, 2022, provides an overview of the Pancreatic Cancer (Oncology) pipeline landscape. Pancreatic cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas. This is also called exocrine cancer. Signs and symptoms include upper abdominal pain that may radiate to back, yellowing of skin and the whites of eyes (jaundice), loss of appetite, weight loss, depression and blood...
-
Product Insights
Esophageal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Esophageal cancer symptoms include cough, difficulty swallowing, chest pain, pressure or burning, and weight loss. Predisposing factors include age, smoking, obesity, and bile reflux. Treatment includes chemotherapy, radiation therapy, and surgery. The Esophageal Cancer pipeline drugs market research report provides an overview of the Esophageal Cancer (Oncology) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Esophageal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA),...